APPENDICES. A systematic review and economic model of the ...

218
Appendix 12
Core symptoms Educational performance Quality of life Adverse events
Severity of side-effects: parent rating [complete
data for n = 31/35 (89%)]
Placebo 2.9 (2.1)
MPH 5 mg 3.0 (1.9)
MPH 10 mg 2.9 (1.9)
Adderall 5 mg 3.1 (1.6)
Adderall 10 mg 2.8 (1.6)
F = 0.18, p = NS
Severity of side-effects: English teacher rating
[complete data for n = 13/35 (37%)]
Placebo 1.9 (1.7)
MPH 5 mg 3.4 (2.1)
MPH 10 mg 2.7 (2.1)
Adderall 5 mg 3.3 (2.4)
Adderall 10 mg 1.9 (1.7)
F = 3.25, p = 0.01
Severity of side effects: maths teacher rating
[complete data for n = 15/35 (43%)]
Placebo 2.2 (1.8)
MPH 5 mg 1.5 (2.0)
MPH 10 mg 2.4 (2.0)
Adderall 5 mg 2.6 (2.6)
Adderall 10 mg 2.3 (2.0)
F = 0.98, p = NS
Severity of side-effects: self-rating
Placebo 2.7 (1.6)
MPH 5 mg 3.3 (2.3)
MPH 10 mg 2.9 (2.2)
Adderall 5 mg 2.5 (1.9)
Adderall 10 mg 2.4 (1.4)
F = 2.42, p = 0.05
Conclusions Authors’ conclusions: Both Adderall and MPH appear to be clinically effective in the treatment of ADHD in teenagers, based on
clinician’s global impressions (data not presented). No significant medication effects could be detected on parent or teacher ratings.
Only teen self-reported ratings of side-effects revealed a significant drug effect, suggesting less severe side-effects on the 10-mg
Adderall dose than the 5-mg MPH dose
Reviewer’s comments: Authors’ conclusions on relative clinical effectiveness of MPH and Adderall are based on unblinded investigator
judgement (data not presented). Incomplete data limited the power to detect significance